Zynerba Pharmaceuticals IncMOEX ZYNE-RM Stock Report

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. The company is headquartered in Devon, Pennsylvania and currently employs 28 full-time employees. The company went IPO on 2015-08-05. Cannabinoids are a class of compounds derived from Cannabis plants. Its two primary cannabinoids contained in cannabis are cannabidiol and tetrahydrocannabinol (THC). The firm is developing Zygel, the pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of THC. Zygel is being developed as a clear gel with once- or twice-daily dosing and is targeting the treatment of behavioral symptoms of FXS, ASD and 22q. The company has evaluated Zygel targeting the reduction of seizures in patients with a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).